…we are planning a study right now using a citizen-scientist approach, says Sonja Lyubomirsky, a psychologist at UC Riverside. We’re going to ask people to get together with a friend and have a deep conversation. We’re going to have a placebo, which may be either a lower dose of the drug, or it could be…
The problem is that in the real world… people with characteristics that would have excluded them from the psilocybin trial are common… exclusion criteria are not the only problematic aspect… of psychedelics, however. Another is the psychotherapeutic component of the treatment, which is currently variable, time-consuming and extensive. In the psilocybin trial mentioned… two therapists…
…LSD and psilocybin activate serotonin receptors on brain cells in a way that reduces the energy needed for the brain to switch between different activity states, according to a study led by Weill Cornell Medicine researchers… “Serotonin 2a receptors have a spatial distribution in the brain that appears to be optimized for lowering these state…
As part of their efforts to better understand DEA’s administrative process, Aggarwal [Washington State, Seattle] and his counsel have submitted several Freedom of Information Act (FOIA) requests for relevant documents. DEA’s FOIA policy states that it will consider waiving or reducing fees if the requester is shows that the information is “in the public interest because…
Just a quarter of a milligram – 0.25 milligrams – can kill you. For a sense of just how little that is, a typical baby aspirin tablet is 81 mg. If you cut that tablet into 324 pieces, one of those pieces would be equal to a quarter-milligram. In the year ending in April 2019,…
When pressed on why the police nor the city have moved to shut the business down – let alone make any arrests – representatives of both have expressed that they’re more concerned with addressing the opioid crisis rather than wrestling with the increasingly embraced psychedelic scene. It probably isn’t a stretch to guess that they…
The durability of treatment could… be challenged by commercial pressure to reduce the psychiatric component of psilocybin therapy, so that the drug can be given to as many people as possible. Charles Raison, a psychiatrist at the University of Wisconsin–Madison who is currently overseeing a phase II clinical trial of psilocybin, is concerned about how…
So, what can we expect from [Oregon] psilocybin production… centers? Mushroom production is considered a commercial farm use and it will require a license, tracking and security (similar to Oregon’s cannabis regulatory system). Growing the mushrooms is a small-scale, indoor, odorless activity and because the psilocybin therapy is long-lasting, only a very small harvest (for…
Published in the Journal, Drug Science, Policy and Law, [with authors Rayyan Zafar and David Nutt (who performed the first MRI of a human brain under the influence of LSD)], from Imperial College London, Centre for Psychedelic Research and Neuropsychopharmacology, UK: this case highlights the plausible therapeutic role of such plant-based medicines in oncology treatment…
In fact, it increasingly seems that pain – one of the most universal experiences in the human condition – is now the next frontier for psychedelics after mental health. “As a non-addictive alternative to opioids, psychedelics represent a revolutionary and much-needed new approach to the treatment of pain,” according to the Psychedelics and Health Research Initiative…
Recent Comments